Over half a million more doses of AstraZeneca COVID-19 vaccine arrived in the Philippines on Friday, further boosting the country's vaccine supply.
Published July 8, 2021, 11:43 AM
The virtual event by AstraZeneca
AstraZeneca Philippines has announced a partnership with health insurance provider, Intellicare, and top local life insurer PRU Life UK to increase patient support in lung cancer diagnosis and treatment.
In the Philippines, cancer is now the 2nd leading cause of death, next to heart disease. In 2018, there were more than 140,000 new cancer cases and more than 86,000 cancer deaths. Among the different types of cancer, lung cancer is the deadliest. Lung cancer accounts for the highest mortality rate among malignancies, with 59 percent of cases diagnosed only after reaching its metastatic stage. At a late stage diagnosis, survival rates drop to as low as 3 percent.
PHILIPPINE STAR/MICHAEL VARCAS
As part of a science-driven industry, the biopharmaceutical industry is leading the way in developing treatments, vaccines, and diagnostics for coronavirus disease 2019 (COVID-19). Our scientists are searching for potentially useful assets that can help with the development of new or repurposed treatments or vaccines to fight against the novel coronavirus. We are leveraging our manufacturing technologies to allow the rapid upscaling of production once a medicine or vaccine candidate is identified to meet the needs of the most affected populations. Phase 3 clinical trials are being conducted to establish safety and efficacy. We are collaborating with governments, global health and research organizations, and pharmaceutical laboratories to share knowledge, libraries, and technologies.
The delivery of coronavirus vaccines from British-Swedish drugmaker AstraZeneca is being delayed by manufacturing complications, vaccine czar Secretary Carlito Galvez Jr. said Thursday.
(Photo by Paul ELLIS / AFP / MANILA BULLETIN)
With the FDA’s approval, Dapagliflozin is the first and only drug under the sodium glucose transport protein 2 inhibitor (SGLT2i) class approved to treat heart failure in adult patients with reduced ejection fraction (pumapalyang puso), AstraZeneca Philippines said in statement.
The multinational pharmaceutical company noted that the Dapagliflozin, a medicine for diabetes, is the only SGLT2i proven to significantly prevent cardiovascular death and death due to other causes among patients with heart failure.
AstraZeneca Philippines Country President Lotis Ramin expressed AstraZeneca’s commitment to uplift the standard of care of Filipino patients by providing them with innovative and accessible treatment.